Indian pharma moves towards automated drug making to appease regulators

India’s second-largest drug maker by sales, Dr Reddy Laboratories Ltd, is increasingly computerizing medicine making, saying the less involved its workers are in the process, the less likely there will be mistakes. It should also mean fewer failed US Food and Drug Administration inspections, said V. Venkatanaryan, the head of the drug maker’s Bachupally plant, and will “…avoid good manufacturing practice pitfalls from regulators,” according to Samiran Das, head of Dr. Reddy’s generic drugs manufacturing. Indian firms currently make 40percent of generic drugs sold in the US.

Read the source article at online.wsj.com

About the Author

Leave a Reply